

### The Key to a Durable Solution

A long-lasting, positive response to acne is to neutralize the sebaceous glands.

Before Treatment

After Treatment



## Company Summary

**CE Mark Clearance obtained March 2020**  
**Pivotal FDA Clinical Trial initiated**



Accure is developing a novel laser targeting sebaceous glands which demonstrated an 80% acne lesion reduction measured 3 months after treatments.

Accure has world-class leadership, clinical and technical teams, formidable clinical research and is building a strong IP position.

Accure has developed a clear, compelling go-to-market strategy, leveraging significant commercialization experience.

## A Unique Solution

### THE ACCURE LASER IS UNIQUE

#### Over-the-Counter Products



#### Isotretinoin (Accutane)



#### Previous Light-based Energy Devices



- Accure targets the sebaceous gland, the key to a durable solution
- Accure utilizes a unique wavelength- never technically feasible until now
- Accure is more than a unique wavelength- patent filings include unique pulsing, integrated temperature monitoring, precise & safe laser control, optimizing efficacy
- The focus is on providing temporary relief to symptoms
- None of these products address the sebaceous glands
- Since none address sebaceous glands, none provide a durable response
- Durability is a concern, since up to half of patients relapse within two years
- Documented side effects: fetal defects, inflammatory bowel disease, suicide attempts
- "Isotretinoin must not be used by female patients who are or may become pregnant" limits treatment options for premenopausal women with hormonal acne
- Previous light-based energy devices used sub-optimal wavelengths
- These treated acne temporarily, often focusing on *p.acnes*
- Since none have addressed the sebaceous glands, none provide a durable response

## An Extraordinary Leadership Team



### Christopher Carlton – Chairman & Chief Executive Officer, Founder

Extensive energy-based aesthetic industry experience including President of the largest company in this space at that time. Executive leadership experience with GE Marquette Medical, Dräger, SRI Surgical and Covidien.

**R. Rox Anderson, MD – Chief Scientific & Medical Officer, Founder** Professor of Dermatology, Harvard Medical School, Director. Considered the "Father" of energy-based aesthetic devices. 2020 Inductee-National Inventors Hall of Fame. 60+ patents, authored 420+ scientific papers, and over 22,000 journal citations.

### Henrik Hofvander – Chief Technology Officer

Extensive laser-based technology experience. Mr. Hofvander is the driving force behind many of the unique technical solutions of the Accure device.

### Vlad Paul-Blanc – Chief Commercial Officer

Successful global leadership roles including product development & commercialization, business development, clinical education and global executive appointments.

### Karl Nicholls, ACMA – Vice President, Finance and Special Projects

Experienced medical device finance executive. Extensive breadth and depth of expertise in start-ups and global companies such as Covidien.